FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898437318> ?p ?o ?g. }

• W2898437318 endingPage "S202" @default.
• W2898437318 startingPage "S202" @default.
• W2898437318 abstract "Ibalizumab (IBA) is a long-acting humanized monoclonal antibody that binds domain 2 of the CD4 receptor and blocks HIV-1 infection of host cells. TMB-301 was a 24-week, Phase 3 clinical trial conducted in 40 heavily treatment-experienced patients with multidrug-resistant (MDR) HIV-1 investigating the safety, efficacy and tolerability of IBA. Patients received a 2,000 mg IBA loading dose followed by 800 mg every 2 weeks by intravenous infusion plus an optimized background regimen. Viral load <50 and <200 HIV RNA copies/mL was achieved in 43% and 50% of patients, respectively, at Week 25. We determined the pharmacokinetic profile of IBA, i.e., serum concentrations, CD4 receptor occupancy (RO), and CD4 receptor density (RD), in these patients with MDR HIV-1. Pre- and post-dose blood samples collected at various time points during trial were used to determine IBA serum concentrations, CD4 RO and RD at trough. IBA serum concentrations were measured using a validated ELISA. IBA bound to CD4+ T cells (RO) and cell surface CD4 levels (RD) were measured simultaneously by flow cytometry using the Molecules of Equivalent Soluble Fluorescence approach. The maximum IBA serum concentrations were observed immediately after the end of the 2,000 mg infusion with mean (SD) of 567 (235) μg/mL. Steady state was reached at Week 4 after the loading dose. The mean IBA concentrations were >30 μg/mL throughout the dosing period. Both Cpeak and Ctrough (Day 7 and Week 25 IBA concentrations) were decreased with increased body weight. The median Ctrough in the high body weight group (≥85 kg) was 0.23 μg/mL. The mean RO was >85% throughout the dosing period. The 2,000 mg loading dose helped to reach >85% RO after the initial dose and maintain high levels of RO throughout the dosing period. Elevation in RO was generally associated with increased IBA serum concentrations; concentrations ≥0.13 μg/mL supported ≥85% CD4 RO. After IBA administration, down-modulation of surface CD4 receptors by up to 20% was observed. There was no apparent association between IBA serum concentration and RD probably due to high inter-individual variation. Dosing regimen of 2,000 mg loading dose followed by 800 mg every 2 weeks was sufficient to support high levels of RO and to maintain the drug concentration above the therapeutic level. P. N. Kumar, TheraTechnologies: Consultant and Investigator, Consulting fee and Research grant. ViiV: Consultant, Investigator and Shareholder, Research grant and Speaker honorarium. Merck: Investigator and Shareholder, Research grant. Gilead: Consultant, Investigator and Shareholder, Consulting fee and Research grant. S. Weinheimer, TaiMed Biologics: Employee, Salary. Z. Cohen, Theratechnologies Inc.: Employee, Salary. C. Marsolais, Theratechnologies Inc.: Employee, Salary. K. L. Kuo, TaiMed Biologics Taiwan: Employee, Salary. S. Lewis, TaiMed Biologics: Employee, Salary." @default.
• W2898437318 created "2018-11-02" @default.
• W2898437318 creator A5000507061 @default.
• W2898437318 creator A5023016883 @default.
• W2898437318 creator A5046709612 @default.
• W2898437318 creator A5070686853 @default.
• W2898437318 creator A5083402039 @default.
• W2898437318 creator A5084535679 @default.
• W2898437318 date "2018-11-01" @default.
• W2898437318 modified "2023-10-16" @default.
• W2898437318 title "544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial" @default.
• W2898437318 doi "https://doi.org/10.1093/ofid/ofy210.552" @default.
• W2898437318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6255274" @default.
• W2898437318 hasPublicationYear "2018" @default.
• W2898437318 type Work @default.
• W2898437318 sameAs 2898437318 @default.
• W2898437318 citedByCount "0" @default.
• W2898437318 crossrefType "journal-article" @default.
• W2898437318 hasAuthorship W2898437318A5000507061 @default.
• W2898437318 hasAuthorship W2898437318A5023016883 @default.
• W2898437318 hasAuthorship W2898437318A5046709612 @default.
• W2898437318 hasAuthorship W2898437318A5070686853 @default.
• W2898437318 hasAuthorship W2898437318A5083402039 @default.
• W2898437318 hasAuthorship W2898437318A5084535679 @default.
• W2898437318 hasBestOaLocation W28984373181 @default.
• W2898437318 hasConcept C112705442 @default.
• W2898437318 hasConcept C126322002 @default.
• W2898437318 hasConcept C142462285 @default.
• W2898437318 hasConcept C197934379 @default.
• W2898437318 hasConcept C203014093 @default.
• W2898437318 hasConcept C2777288759 @default.
• W2898437318 hasConcept C2778375690 @default.
• W2898437318 hasConcept C2781413609 @default.
• W2898437318 hasConcept C3013748606 @default.
• W2898437318 hasConcept C553184892 @default.
• W2898437318 hasConcept C71924100 @default.
• W2898437318 hasConcept C90924648 @default.
• W2898437318 hasConcept C98274493 @default.
• W2898437318 hasConceptScore W2898437318C112705442 @default.
• W2898437318 hasConceptScore W2898437318C126322002 @default.
• W2898437318 hasConceptScore W2898437318C142462285 @default.
• W2898437318 hasConceptScore W2898437318C197934379 @default.
• W2898437318 hasConceptScore W2898437318C203014093 @default.
• W2898437318 hasConceptScore W2898437318C2777288759 @default.
• W2898437318 hasConceptScore W2898437318C2778375690 @default.
• W2898437318 hasConceptScore W2898437318C2781413609 @default.
• W2898437318 hasConceptScore W2898437318C3013748606 @default.
• W2898437318 hasConceptScore W2898437318C553184892 @default.
• W2898437318 hasConceptScore W2898437318C71924100 @default.
• W2898437318 hasConceptScore W2898437318C90924648 @default.
• W2898437318 hasConceptScore W2898437318C98274493 @default.
• W2898437318 hasIssue "suppl_1" @default.
• W2898437318 hasLocation W28984373181 @default.
• W2898437318 hasLocation W28984373182 @default.
• W2898437318 hasLocation W28984373183 @default.
• W2898437318 hasOpenAccess W2898437318 @default.
• W2898437318 hasPrimaryLocation W28984373181 @default.
• W2898437318 hasRelatedWork W1736016875 @default.
• W2898437318 hasRelatedWork W2037651778 @default.
• W2898437318 hasRelatedWork W2328878243 @default.
• W2898437318 hasRelatedWork W2775663577 @default.
• W2898437318 hasRelatedWork W2803051518 @default.
• W2898437318 hasRelatedWork W2922882148 @default.
• W2898437318 hasRelatedWork W3087516196 @default.
• W2898437318 hasRelatedWork W3197824728 @default.
• W2898437318 hasRelatedWork W3207313530 @default.
• W2898437318 hasRelatedWork W1962564742 @default.
• W2898437318 hasVolume "5" @default.
• W2898437318 isParatext "false" @default.
• W2898437318 isRetracted "false" @default.
• W2898437318 magId "2898437318" @default.
• W2898437318 workType "article" @default.